Benzinga | Aug 9, 2021 02:05PM EDT

NRx Pharma Starts Mid-Stage COVID-19 Vaccine Trial In Nation of Georgia

* NRx Pharmaceuticals Inc (NASDAQ:NRXP) has initiated a phase 2b dose-confirmatory trial of the BriLife vaccine against COVID-19 in the Nation of Georgia.

* The vaccine is developed by the Israel Institute for Biological Research (IIBR).

* The purpose of the study is to confirm the vaccine's ability to generate an immune response against the COVID-19 Delta variant before entering phase 3 trials in multiple nations.

* The phase 2b program will also incorporate a potential intradermal vaccination option. A small quantity of vaccine will be placed into the skin instead of a traditional needle injection into a muscle.

* The clinical trials in Georgia will take place simultaneously as the completion of the second phase of clinical trials in Israel.

* In July, NRx Pharma's intravenous Zyesami (aviptadil) to treat critical COVID-19 patients received Emergency Use Authorization in the Nation of Georgia.

* Price Action: NRXP shares are up 12.90% at $15.51 during the market session on the last check Monday.